Entity

Time filter

Source Type

Nova Londrina, Brazil

Kuasne H.,State University Londrina | Rodrigues I.S.,State University Londrina | Fuganti P.E.,Londrina Hospital of Cancer | Losi-Guembarovski R.,State University Londrina | And 6 more authors.
Cancer Investigation | Year: 2010

The study of genes involved in androgen pathway can contribute to a better knowledge of prostate cancer. Our aim was to examine if polymorphisms in prostate-specific antigen (PSA) and androgen receptor (AR) genes were involved in prostate cancer risk and aggressiveness. Genotypes were determined by PCR-RFLP (PSA) or using a 377 ABI DNA Sequencer (AR). PSA(G/G) genotype (OR=1.78, 95% CI=1.06-2.99) and AR short CAG repeats (OR=1.89, 95% CI=1.21-2.96) increased risk for prostate cancer and were related with tumor aggressiveness. About 38.3 of tumors showed microsatellite instability. In conclusion, polymorphisms in these genes may be indicated as potential biomarkers for prostate cancer. © 2010 Informa Healthcare USA, Inc. Source


Kuasne H.,State University Londrina | Rodrigues I.S.,State University Londrina | Losi-Guembarovski R.,State University Londrina | Reis M.B.,State University Londrina | And 7 more authors.
Molecular Biology Reports | Year: 2011

Prostate cancer is the second cause of cancer death in Brazilian men. One of the relevant phenomena to the inherited susceptibility is the presence of allelic variants in genes involved with the DNA repair pathway. The aim of this study was to analyze the frequencies of prevalent, heterozygous and rare genotypes of the base excision repair genes APEX1 and XRCC1 in a case-control study and relate the genotypes with tumoral aggressiveness. DNA from peripheral blood of 172 patients and 172 controls were analyzed by RFLP-PCR method. The polymorphisms were also evaluated in relation to clinical and pathological parameters. The OR (Odds Ratio) and confidence interval (CI = 95%) were used in the association study and the Chi-square and ANOVA tests for the evaluation of histopathological parameters. The rare genotypes frequencies of the gene APEX1 increased the risk for the development of prostate cancer (OR = 1.68 95% CI 1.10-2.58). No association was found for the gene XRCC1 (OR = 0.82 95% CI 0.53-1.27). The combined analysis for both genes did not show association with this neoplasia (OR = 1.27 95% CI 0.79-20.5). The relationship of XRCC1 and APEX1 genotypes with cancer aggressiveness through the correlation with histopathological parameters, did not find any association. Our results suggest that the polymorphism in the gene APEX1 may be indicated as a potential marker for prostate cancer risk. © 2010 Springer Science+Business Media B.V. Source

Discover hidden collaborations